2. Academic Validation
  3. Discovery of (2 R,4 R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer

Discovery of (2 R,4 R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer

  • J Med Chem. 2024 Dec 12;67(23):20827-20841. doi: 10.1021/acs.jmedchem.4c02309.
Scott N Mlynarski 1,  Brian M Aquila 1,  Susan Cantin 1,  Steve Cook 2,  Aatman Doshi 1,  M Raymond V Finlay 3,  Eric T Gangl 1,  Tyler Grebe 1,  Chungang Gu 1,  Sameer P Kawatkar 1,  Jens Petersen 4,  Petar Pop-Damkov 1,  Alwin G Schuller 1,  Wenlin Shao 1,  Jason D Shields 1,  Iain Simpson 3,  Siavash Tavakoli 4,  Sharon Tentarelli 1,  Scott Throner 1,  Haixia Wang 1,  Jianyan Wang 2,  Dedong Wu 2,  Qing Ye 1
Affiliations

Affiliations

  • 1 Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States.
  • 2 Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca, Waltham 02451, Massachusetts, United States.
  • 3 Early Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • 4 Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Mölndal SE-431 83, Sweden.
PMID: 39572889 DOI: 10.1021/acs.jmedchem.4c02309
Abstract

Arginase is a promising immuno-oncology target that can restore the innate immune response. However, it's highly polar active site often requires potent inhibitors to mimic Amino acids, leading to poor passive permeability and low oral exposure. Using structure-based drug design, we discovered a novel proline-based Arginase Inhibitor (10) that was potent but had low oral bioavailability in rat. This issue was addressed by incorporating Amino acids to target PepT1/2 active transport, followed by in vivo hydrolysis post absorption. The hydrolysis rate was highly tunable, and the valine prodrug (19) showed the best balance of stability and exposure of the potent payload. Dosing of 19 in mouse xenograft models significantly increased arginine in the tumor microenvironment, resulting in tumor growth inhibition as a monotherapy and in combination with an anti-PD-L1 antibody. Compound 19 (AZD0011) displays good pharmacokinetics and was selected as a clinical drug candidate for Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-182719
    精氨酸酶1抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z